Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 19/20 | 0.82 |
| ▸ | PLK3 | Q9H4B4 | 7/20 | 0.82 |
| ▸ | CDK2 | P24941 | 1/20 | 0.82 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.82 |
| ▸ | NEK2 | P51955 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gsk-237701A SCHEMBL4034890 | 0.90 | PLK1 (1.00) | PLK1PLK3CDK2IKBKENEK2 | |
| Gsk-237701A SCHEMBL29644977 | 0.90 | PLK1 (1.00) | PLK1PLK3CDK2IKBKENEK2 | |
| Gsk-237701A SCHEMBL5065885 | 0.90 | PLK1 (1.00) | PLK1PLK3CDK2IKBKENEK2 | |
| SCHEMBL4035216 | 0.88 | PLK1 (0.83) | PLK1PLK3CDK2IKBKENEK2 | |
| SCHEMBL13206495 | 0.88 | PLK1 (0.83) | PLK1PLK3CDK2IKBKENEK2 | |
| SCHEMBL3259195 | 0.86 | PLK1 (0.80) | PLK1PLK3CDK2IKBKECYP2C9 | |
| SCHEMBL13440184 | 0.86 | PLK1 (0.80) | PLK1PLK3CDK2IKBKECYP2C9 | |
| SCHEMBL14344449 | 0.85 | PLK1 (0.81) | PLK1PLK3CDK2IKBKECYP2C9 | |
| SCHEMBL3736969 | 0.84 | PLK1 (0.60) | PLK1PLK3CDK2IKBKECYP2C9 | |
| SCHEMBL14344537 | 0.83 | PLK1 (0.74) | PLK1PLK3CDK2IKBKECYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060074119-A1 | Thiophene compounds | SMITHKLINE BEECHAM CORPORATION | 2006-04-06 | — | — | US | claimed |
| EP-1546137-A1 | BENZIMIDAZOL-1-YL-THIOPHENE COMPOUNDS FOR THE TREATMENT OF CANCER | SmithKline Beecham Corporation (US) | 2005-06-29 | — | — | EP | claimed |
| WO-2004014899-A1 | THIOPHENE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-02-19 | — | — | WO | claimed |
| US-20080269298-A1 | Benzimidazol-1-YL-thiophene compounds for the treatment of cancer | ANDREWS CLARENCE W | 2008-10-30 | — | — | US | disclosed |
| US-20060074119-A1 | Thiophene compounds | SMITHKLINE BEECHAM CORPORATION | 2006-04-06 | — | — | US | disclosed |
| EP-1546137-A1 | BENZIMIDAZOL-1-YL-THIOPHENE COMPOUNDS FOR THE TREATMENT OF CANCER | SmithKline Beecham Corporation (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004014899-A1 | THIOPHENE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074119-A1 | Thiophene compounds | TPMT, ABCB1, CYP3A5 | PLK1 2123/4885PLK3 3731/4885CDK2 856/4885 |
| US-20080269298-A1 | Benzimidazol-1-YL-thiophene compounds for the treatment of cancer | ABCB1, TP53, CCNI | PLK1 130/4885PLK3 1224/4885CDK2 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.